

September 11, 2025

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

## Notice Concerning Revisions to Full-Year Financial Results Forecasts

CellSource Co., Ltd. (the "Company") hereby announces that the consolidated financial results forecasts for the fiscal year ending October 31, 2025 (November 1, 2024 through October 31, 2025), disclosed on December 12, 2024, have been revised as described below.

### 1. Revisions to consolidated financial results forecasts for the current fiscal year

(November 1, 2024 through October 31, 2025)

	Net sales	Operating profit	Ordinary profit	Profit	Earnings per share
Previously announced forecasts (A)	Millions of yen 4,501	Millions of yen 370	Millions of yen 372	Millions of yen 255	Yen 12.88
Revised forecasts (B)	3,744	203	205	112	5.65
Change (B-A)	-727	-167	-167	-143	-7.23
Change (%)	-16.2%	-45.1%	-44.9%	-56.1%	-

\*Since the Company transitioned to consolidated financial statements starting with the fiscal year ending October 2025, figures for the fiscal year ending October 2024 are not provided.

### 2. Reasons for the revisions

At the end of the third quarter, it became clear that our net sales for the current period would fall below our initial forecast due to changes in the contract terms for medical institution support services.

Furthermore, a significant expansion of sales in our other businesses is also difficult to foresee. In light of this sales decrease and future outlook, we anticipate a corresponding decline in profit. Therefore, in order to appropriately reflect the situation as of now, we have decided to revise our full-year earnings forecast for both net sales and each profit item.

For the current fiscal year, we had projected an increase in revenue, driven by a rise in orders for our core business, contract processing services, as well as the launch of medical institutions support services, which were expected to have a synergistic effect. However, the measures to increase orders for contract processing services took longer than anticipated to show results. Although sales have increased, they had not reached the expected level by the end of the third quarter, which led to a revision of our forecast.

Additionally, we reduced the scope of our support contracts for medical institutions support services from our initial plan, based on discussions with the target medical institutions.

Regarding the net sales for the fourth quarter, we project that the number of orders for contract processing services for medical institutions specializing in self-funded treatments will remain flat, while those for hybrid type institutions are expected to increase from the previous quarter with the new measures taking effect. For medical institutions support services, we anticipate sales based on the contracts mentioned above. Sales for both medical device sales and cosmetics sales are expected to remain approximately unchanged from previous periods.

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*